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Abstract: ABO blood groups and secretor status are important in clinical and forensic medicine 
and in relation to some diseases. There are geographic and racial differences in their frequencies, 
but the frequency of secretor status in different ABO blood group systems has not been deter-
mined yet. Therefore, the aim of this study was mainly to determine this point. Blood and saliva 
from 762 randomly selected apparently healthy adult individuals (480 men and 282 women) were 
examined to determine their ABO and Rhesus blood groups by standard conventional methods, 
and their secretor status by using Lewis blood grouping and/or   hemagglutination inhibition test 
of saliva. Results showed that 76.1% of the study population were ABH blood group antigens 
secretors and 23.9% were nonsecretors. The frequencies of secretor status in different ABO blood 
groups were 70.1% in group A, 67.8% in group B, 67.9% in group AB, and 88.3% in group O. 
In conclusion, blood group O individuals have significantly higher frequency of secretor status 
than non-O blood group individuals. This finding would be beneficial to them, protecting them, 
at least partially, from certain malignancies or allowing them to have less aggressive disease, 
and this finding might be useful in enhancing further studies and research in this direction.
Keywords: blood group O, ABO blood groups, secretor phenotype, frequency, malignancies, 
prevention and/or treatment
Introduction
In 1930, it was found that individuals could be classified as ‘secretors’ and ‘nonsecretors’ 
according to their ability to secrete ABO blood group antigens in saliva.1 ABO blood 
group antigens (A, B, and H), in addition to their presence on blood cells and plate-
lets, are also present on other tissue cells and are variably expressed through body 
fluids, such as saliva, tears, semen, urine, gastric juice, and breast milk, depending on 
whether the individual possesses the secretor gene or not, the inherited A, B, O genes, 
and Lewis blood group system.2
In addition to ABO blood group applications in blood transfusion and forensic medi-
cine, numerous studies have found strong relations between individuals’ susceptibilities 
to some diseases and their ABO blood groups,3 as well as their secretor status.4
The secretor gene encodes for enzymes (glycosyltransferases), which become active 
in mucin-secreting cells like goblet and mucous cells of mucous membranes and different 
glands, resulting in the secretion of the corresponding blood group antigens in the body 
fluids.5 H antigen that is present on the cells of individuals with O blood group is the base 
for A and B antigens, but A and B antigens differ only in their added terminal sugars, 
which are controlled by specific enzymes called transferase enzymes. These enzymes 
are under the control of inherited genes, which are A, B, H (FUT1) genes and secretor International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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(FUT2) genes.6 H (FUT1) and secretor (FUT2) genes are sepa-
rate but closely linked. Lewis blood group phenotypes are also 
important in determining the secretor status of an individual, 
as Lewis genes (FUT3) are closely linked to secretor (FUT2) 
and H (FUT1) genes.7,8 Subjects are either Lewis negative or 
Lewis positive. In Lewis-negative individuals, the secretor 
genotype does not affect the Lewis phenotype. However, in 
Lewis-positive individuals, the secretor genotype generates 
either the nonsecretor phenotype Le(a+b−) or the secretor 
phenotype Le(a−b+), or the partial secretor genotype, which 
gives rise to a transient Le(a+b+) phenotype.9 Therefore, 
practically, there are only three Lewis phenotypes: Le(a+b−), 
Le(a−b+), and Le(a−b−).
The frequencies of different Lewis-secretor phenotypes 
vary markedly among different ethnic populations.10 It is 
generally known that about 80% of the world’s population 
are secretors of ABH antigens and only 20% are nonsecretors 
but with some racial differences.8 One of the studies in our 
region showed that 78% of Kurds are secretors and 22% of 
them are nonsecretors.11
Because most secretors have a Lewis blood group of 
Le(a−b+) phenotype and most nonsecretors have a Lewis 
blood group of Le(a+b−) phenotype, Lewis blood grouping 
is used to detect the secretor status of most of the popula-
tion. Only a minority of the population (5%–10%)12,13 have 
Le(a−b−) phenotype, ie, Lewis double negative (LDN). For 
these people, as the standard Lewis blood grouping cannot 
be used to determine their secretor status, saliva testing by 
the standard hemagglutination inhibition test is used.14
To the best of our knowledge, there are no reports on the 
incidence of secretor status in different ABO blood groups 
(A, B, AB, and O), and to investigate this point we planned 
this study.
Materials and methods
Seven hundred and sixty-two apparently healthy unre-
lated adults (480 men and 282 women) were randomly 
selected and asked to volunteer for this study, after they 
were informed about its aim. This study was carried out 
in Hawler Teaching Hospital Laboratory, Erbil, Kurdistan 
Region, Iraq, in the period between January 2008 and 
May 2010.
From each individual, 3 mL of blood was taken into ster-
ile plain tubes. Subjects were informed to rinse their mouth 
with water prior to saliva collection. After chewing a piece of 
paraffin wax, to stimulate secretion of saliva, 5 mL of saliva 
was collected in sterile plain glass tubes. Saliva samples were 
tested within 2 h of collection.
ABO and Rhesus blood grouping was performed on 
saline-washed red blood cells using commercial antisera kits: 
monoclonal anti-A, anti-B antisera (Plasmatec Laboratory 
Products Ltd., Bridport, Dorset, UK), and monoclonal anti-
H antiserum (Seraclone, Biotest, Dreieich, Germany) by the 
standard conventional hemagglutination technique.
Lewis blood group phenotype was also performed on 
the saline-washed RBCs by the standard hemagglutina-
tion technique using monoclonal anti-Le(a) and anti-Le(b) 
(Lorne Labs, Reading, Berkshire, UK) according to the 
manufacturer’s instructions. Individuals with Le(a−b+) were 
assigned as secretors, those with Le(a+b−) were assigned 
as nonsecretors, and those with Le(a−b−), ie, LDN, were 
assigned unknown secretor status, for whom saliva was used 
to determine their secretor status by the standard hemagglu-
tination inhibition test.
Statistical analysis was performed using Windows 
  software, Microsoft Office Excel 2003. χ2 tests and t-test were 
used to determine the significance of the influence of sex, 
Rh type, and different ABO blood groups on the frequency of 
secretor status among the study population. P values ,0.05 
were regarded as significant.
Results
The total number of participants in this study was 762 
(480 men and 282 women). Their age ranged between 19 and 
45 years with a median of 34 years. The frequencies of Lewis 
blood group phenotypes Le(a+b−), Le(a−b+), and Le(a−b−) 
are shown in Table 1. Saliva test was done on 84   individuals 
with Le(a−b−) phenotype and showed that 60 (71%) of them 
were secretors and 24 (29%) were   nonsecretors. Secretor and 
nonsecretor status formed 76.1% and 23.9% of the study 
population, respectively. In men, 75.6% were   secretors 
and 24.4% were nonsecretors, while in women 74.1% 
were secretors and 25.9% were nonsecretors (Table 2). In 
Rh(D)-positive individuals, 76% were   secretors and 24% 
were nonsecretors, while in Rh(D)-negative individuals 
77% were secretors and 23% were nonsecretors (Table 3). 
Statistically, no significant differences were found in the 
secretor status between men and women (P . 0.05) as well 
Table 1 Frequency of Lewis blood group phenotype in the study 
population
Lewis phenotype Secretors Nonsecretors Total
Le(a+b−) 0 0% 158 100% 158 20.7%
Le(a−b+) 520 100% 0 0% 520 68.3%
Le(a−b−) 60 71.4% 24 28.6% 84 11.0%
Total 580 76.1 182 23.9 762 100%International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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as between Rh(D)-positive and Rh(D)-negative individuals 
(P . 0.05).
The distribution of ABO blood groups in the study popu-
lation and the incidence of secretor status in different ABO 
blood groups are shown separately in Table 4. There was a 
highly significant increase in the incidence of secretor status 
in O blood group individuals when compared with A, B, 
and AB blood group individuals separately (P , 0.0001, 
P , 0.0001, P = 0.0003, respectively) and collectively 
(P , 0.0001). However, there were no significant differences 
in the incidence of secretor status in A, B, and AB blood 
groups when compared with each other (P . 0.05 for all 
comparisons) (Table 5).
Discussion
The incidence of secretor status in men and women and in 
Rh(D) group was in concordance with our previous study11 
and similar to many other studies.15 This significant increased 
incidence of secretor status in blood group O individuals in 
this study was not, to the best of our knowledge, recorded 
in the literature reviewed. This may at least, to some extent, 
explain the low incidence of certain diseases in blood group O 
individuals. Many published data from large cohort studies 
from different parts of the world suggest low incidence of 
many malignancies16 in group O compared with group A, 
eg, gastric carcinoma,17 oral cancerous lesions,18,19 lung,20,21 
colon,22 ovarian cancer,23 pancreatic carcinoma,24,25 prostatic 
carcinoma,26 bladder cancer,27 breast cancer,28 and acute 
leukaemia.29
Blood group O also appears to exert a protective effect 
by preventing the growth and spread of tumors and being 
associated with longer survival times in cancer patients.30 
The following will correlate our finding to, and might 
explain, the above finding. Thomsen-Friedenreich antigen 
(TF), which was discovered in the late 1920s,31 is the core 
disaccharide structure of ABO blood group (H) substance. 
It is cryptic on cell membranes of various normal cells, 
including epithelial cells, red blood cells, and lympho-
cytes. During carcinogenesis, it appears with several other 
different tumor-associated glycol antigens. It is expressed 
in many carcinomas, including those of the breast, colon, 
bladder, and prostate (pan-carcinoma marker), and becomes 
immunoreactive.32
It has been postulated that TF has a role in adhesion 
and metastasis through tumor–endothelial-cell interactions, 
which is the key role in cancer metastasis,33 and through 
binding ligands such as galectins or other lectins34 in sites 
of metastatic tumor growth, ie, in the vascular endothelium, 
liver, bone marrow, and lymph nodes.35 Due to antigenic 
similarity of TF to A antigen, blood group A individuals have 
the least aggressive humoral immune response against the 
TF than group O individuals, so it might be readily confused 
by the immune system of blood group A individuals.32
Humans normally possess natural anti-TF antibodies (IgM), 
which are commonly induced in the gut, as many gram-negative 
organisms carry TF antigen, and people recovering from Escher-
ichia coli enteritis and after infection with Helicobacter pylori 
apparently have higher levels of anti-TF antibodies.36
Table 2 Distribution and comparison of secretor status prevalence 
in men and women
Gender Male Female Total P
secretors 368 75.6% 212 74.1% 580 76.1% .0.05
Nonsecretors 112 24.4% 70 25.9% 182 23.9% –
Total 480 36.0% 282 37.0% 762 100% –
Table 3 Distribution and comparison of secretor status frequency 
in rh(D)-positive and rh(D)-negative individuals
Rhesus type Rh-positive Rh-negative Total P
secretors 532 76% 48 77% 580 76.1% .0.05
Nonsecretors 168 24% 14 23% 182 23.9% –
Total 700 91.8% 62 8.1% 762 100% –
Table 4 Frequency of secretor status in A, B, AB, and O blood 
group individuals
Blood group Secretors Nonsecretors Total
A 171 70.1% 73 29.9% 244 32.0%
B 124 67.8% 59 32.2% 183 24.0%
AB 36 67.9% 17 32.1% 53 7.0%
O 249 88.3% 33 11.7% 282 37.0%
Total 580 75.1% 182 23.9% 762 100%
Table 5 comparison of blood group O secretor status prevalence 
with A, B, and AB blood groups separately and collectively
Blood groups, 
secretors/totals 
(%)
A 
(171/244) 
(70.1%)
B 
(124/183) 
(67.8%)
AB 
(36/53) 
(67.9%)
A + B + AB 
(331/480) 
(69.0%)
A 
(171/244) 
(70.1%)
– P = 0.074 P = 0.122 P = 0.065
B 
(124/183) 
(67.8%)
P = 0.074 – P = 0.133 P = 0.071
AB 
(36/53) 
(67.9%)
P = 0.122 P = 0.133 – P = 0.122
O 
(249/282) 
(88.3%)
P , 0.0001 P , 0.0001 P = 0.00031 P , 0.0001International Journal of Nanomedicine 2010:5 submit your manuscript | www.dovepress.com
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Interestingly, these bacteria grow more readily in blood 
group O individuals and secretors than non-O individuals, 
which means that they have more natural anti-TF IgM and 
IgG antibody production and probably are less susceptible 
to cancer or have less aggressive disease.37 Higher levels of 
naturally occurring anti-TF antibody also appear to confer 
better prognosis.38 Studies have also shown that secretors 
have the highest natural anti-TF IgM level irrespective of 
ABO phenotype.
Passive transfer of an anti-TF-Ag monoclonal antibody 
in animal experimental trials has significantly resulted in 
extending the median survival time of animals bearing 
metastatic 4T1 breast tumors and caused more than 50% 
inhibition of lung metastasis.39
This means that individuals with O blood group, secretors, 
and postinfection with E. coli are strong responders of anti-TF 
antibody production together or independently, whether they 
are normal or cancer patients.
Von Willebrand factor (vWf) serves as an adhesive link 
between platelets and the endothelium. Several reports have 
demonstrated increased vWf antigen levels in the plasma 
of patients with ovarian, bladder, and colon cancers, with 
increased vWf antigen correlating with more metastasis and 
poor prognosis.40
In fact, secretor genetics appears to interact with ABO 
genetics to influence the plasma levels of vWf, with non-
secretors and non-O blood groups having the highest vWf 
concentrations, and the group O secretors having the lowest 
concentration of vWf:Ag and VIII:Ag.41
All these findings, collectively, lead us to the hypothesis 
that these tumors have more chance to thrive in A blood 
group patients and be more aggressive than in O blood group 
patients. In addition to the contribution of the above findings 
to the explanation of less aggressiveness of these malignan-
cies in O blood group patients, it might also contribute to 
the explanation of the association of blood group O with 
other diseases.
In conclusion, blood group O individuals have significantly 
higher incidence of secretor status than non-O blood group 
individuals. Therefore, it is speculated that with the help of 
this finding and the above information from other studies, 
blood group O individuals with higher natural anti-TF IgM, 
lower levels of vWf, and higher susceptibility to infection by 
H. pylori and gram-negative intestinal flora are benefited and 
protected, at least partially, from certain malignancies or have 
less aggressive diseases. Also, we might be able to speculate 
that this finding might be useful in enhancing further studies 
and research in this direction.
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